全文获取类型
收费全文 | 687篇 |
免费 | 31篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 11篇 |
妇产科学 | 12篇 |
基础医学 | 65篇 |
口腔科学 | 6篇 |
临床医学 | 54篇 |
内科学 | 146篇 |
皮肤病学 | 4篇 |
神经病学 | 30篇 |
特种医学 | 98篇 |
外科学 | 107篇 |
综合类 | 26篇 |
一般理论 | 2篇 |
预防医学 | 67篇 |
眼科学 | 11篇 |
药学 | 30篇 |
中国医学 | 5篇 |
肿瘤学 | 47篇 |
出版年
2023年 | 3篇 |
2022年 | 5篇 |
2021年 | 2篇 |
2020年 | 7篇 |
2018年 | 5篇 |
2017年 | 4篇 |
2016年 | 8篇 |
2015年 | 7篇 |
2014年 | 17篇 |
2013年 | 30篇 |
2012年 | 34篇 |
2011年 | 30篇 |
2010年 | 17篇 |
2009年 | 30篇 |
2008年 | 26篇 |
2007年 | 17篇 |
2006年 | 21篇 |
2005年 | 20篇 |
2004年 | 9篇 |
2003年 | 9篇 |
2002年 | 14篇 |
2001年 | 16篇 |
2000年 | 21篇 |
1999年 | 23篇 |
1998年 | 21篇 |
1997年 | 22篇 |
1996年 | 20篇 |
1995年 | 14篇 |
1994年 | 10篇 |
1993年 | 18篇 |
1992年 | 14篇 |
1991年 | 17篇 |
1990年 | 22篇 |
1989年 | 16篇 |
1988年 | 20篇 |
1987年 | 20篇 |
1986年 | 19篇 |
1985年 | 26篇 |
1984年 | 18篇 |
1983年 | 11篇 |
1982年 | 11篇 |
1981年 | 8篇 |
1980年 | 4篇 |
1979年 | 3篇 |
1978年 | 9篇 |
1977年 | 10篇 |
1976年 | 2篇 |
1975年 | 4篇 |
1972年 | 2篇 |
1969年 | 2篇 |
排序方式: 共有722条查询结果,搜索用时 15 毫秒
11.
12.
Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III 总被引:1,自引:0,他引:1
Cox-Brinkman J van Breemen MJ van Maldegem BT Bour L Donker WE Hollak CE Wijburg FA Aerts JM 《Journal of inherited metabolic disease》2008,31(6):745-752
Summary We report three siblings with Gaucher disease type III, born between 1992 and 2004. During this period, new developments resulted
in different potential therapies, changing clinical practice. The two eldest siblings received enzyme replacement therapy
(ERT) from the age of 24 and 5 months respectively, later followed by an increase in dosage. ERT was combined with substrate
reduction therapy (SRT) from the ages of 12 and 8 years, respectively. In the youngest sibling the combination of high-dose
ERT and SRT was given from the age of 5 months. The two eldest siblings showed significant neurological impairment from the
age of 1.5 years, starting with a convergent strabismus and partial oculomotor apraxia, followed by cognitive decline and
an abnormal EEG and BAER. In contrast, the neurological development in the youngest sibling is almost completely normal. At
the age of 3 years, cognitive development, EEG and BAER are all normal. Disturbed saccadic eye movements, which were already
present at the start of therapy, remained stable. In addition to the clinical efficacy, we report on the biochemical response
to therapy. Based on our results, the combination of high-dose ERT and SRT should be considered as a possible therapeutic
approach for GD III, especially if started at a young age. Further follow-up studies are necessary to explore the long-term
therapeutic effects.
Competing interests: F.A. Wijburg provides consultancy services for Genzyme Corporation.
References to electronic databases: Glucocerebrosidase, EC 3.2.1.45. Gaucher disease type I, OMIM #230800. Gaucher disease type II, OMIM #230900. Gaucher disease
type III, OMIM #231000. 相似文献
13.
Tara Donker Katherine Petrie Judy Proudfoot Janine Clarke Mary-Rose Birch Helen Christensen 《Journal of medical Internet research》2013,15(11)
Background
The rapid growth in the use of mobile phone applications (apps) provides the opportunity to increase access to evidence-based mental health care.Objective
Our goal was to systematically review the research evidence supporting the efficacy of mental health apps for mobile devices (such as smartphones and tablets) for all ages.Methods
A comprehensive literature search (2008-2013) in MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, PsycINFO, PsycTESTS, Compendex, and Inspec was conducted. We included trials that examined the effects of mental health apps (for depression, anxiety, substance use, sleep disturbances, suicidal behavior, self-harm, psychotic disorders, eating disorders, stress, and gambling) delivered on mobile devices with a pre- to posttest design or compared with a control group. The control group could consist of wait list, treatment-as-usual, or another recognized treatment.Results
In total, 5464 abstracts were identified. Of those, 8 papers describing 5 apps targeting depression, anxiety, and substance abuse met the inclusion criteria. Four apps provided support from a mental health professional. Results showed significant reductions in depression, stress, and substance use. Within-group and between-group intention-to-treat effect sizes ranged from 0.29-2.28 and 0.01-0.48 at posttest and follow-up, respectively.Conclusions
Mental health apps have the potential to be effective and may significantly improve treatment accessibility. However, the majority of apps that are currently available lack scientific evidence about their efficacy. The public needs to be educated on how to identify the few evidence-based mental health apps available in the public domain to date. Further rigorous research is required to develop and test evidence-based programs. Given the small number of studies and participants included in this review, the high risk of bias, and unknown efficacy of long-term follow-up, current findings should be interpreted with caution, pending replication. Two of the 5 evidence-based mental health apps are currently commercially available in app stores. 相似文献14.
M. A. Sikma E. M. van Maarseveen E. A. van de Graaf J. H. Kirkels M. C. Verhaar D. W. Donker J. Kesecioglu J. Meulenbelt 《American journal of transplantation》2015,15(9):2301-2313
Annually, about 8000 heart and lung transplantations are successfully performed worldwide. However, morbidity and mortality still pose a major concern. Renal failure in heart and lung transplant recipients is an essential adverse cause of morbidity and mortality, often originating in the early postoperative phase. At this time of clinical instability, the kidneys are exposed to numerous nephrotoxic stimuli. Among these, tacrolimus toxicity plays an important role, and its pharmacokinetics may be significantly altered in this critical phase by fluctuating drug absorption, changed protein metabolism, anemia and (multi‐) organ failure. Limited understanding of tacrolimus pharmacokinetics in these circumstances is hampering daily practice. Tacrolimus dose adjustments are generally based on whole blood trough levels, which widely vary early after transplantation. Moreover, whole blood trough levels are difficult to predict and are poorly related to the area under the concentration‐time curve. Even within the therapeutic range, toxicity may occur. These shortcomings of tacrolimus monitoring may not hold for the unbound tacrolimus plasma concentrations, which may better reflect tacrolimus toxicity. This review focuses on posttransplant tacrolimus pharmacokinetics, discusses relevant factors influencing the unbound tacrolimus concentrations and tacrolimus (nephro‐) toxicity in heart and lung transplantation patients. 相似文献
15.
Ether lipids (EL) and hyperthermia have been shown to possess a relatively selective cytotoxicity to leukemic cells. In this study, the combined effects of EL (ET-18-OCH3, ET-16-NHCOCH3, or BM 41.440) and hyperthermia on the growth of hematopoietic progenitors, myeloid leukemic cell lines, and leukemic cells obtained from patients with acute myeloid leukemia (AML) were examined to determine if this combination resulted in a greater selective killing of leukemic cells than that achieved by either EL or heat alone. When the cells were treated simultaneously with EL (50 micrograms/mL) and hyperthermia (42 degrees C) for one hour, the killing of leukemic cell line cells was enhanced considerably. Among the three EL, however, the combination of ET-18-OCH3 and heat seemed to be the most cytotoxic to leukemic cell line cells with no effect on the growth of hematopoietic progenitors. An increase in the duration of treatment with ET-18-OCH3 to four hours with heat added during the last hour resulted in a further reduction of leukemic cell line cells while sparing 50% of hematopoietic progenitors after cryopreservation. The combined treatment with ET-18-OCH3 and heat also inhibited the growth of leukemic progenitors obtained from AML patients by 97% to 100%. These data indicate that the combined treatment with EL and hyperthermia might offer an efficient means to eliminate myeloid leukemic cells in vitro. 相似文献
16.
Mila Donker MD Caroline A. Drukker MD Renato A. Valdés Olmos MD PhD Emiel J. Th. Rutgers MD PhD Claudette E. Loo MD Gabe S. Sonke MD PhD Jelle Wesseling MD PhD Tanja Alderliesten PhD Marie-Jeanne T. F. D. Vrancken Peeters MD PhD 《Annals of surgical oncology》2013,20(8):2569-2575
Background
Radioguided occult lesion localization (ROLL) with technetium-99 m colloid (ROLL-99mTc) is commonly used to perform breast-conserving surgery in patients with nonpalpable breast tumors. Radioactive seed localization is a relatively new technique that localizes the tumor with a radioactive iodine-125 (125I) seed. The feasibility and outcome of these techniques after neoadjuvant systemic treatment has not been widely investigated.Methods
All patients treated with neoadjuvant systemic treatment between 2007 and 2010 in the Netherlands Cancer Institute who underwent breast-conserving surgery with the ROLL-99mTc technique (n = 83) or with 125I seed localization (n = 71) were analyzed. The weight of the resected specimen, the margins, and the percentage of patients requiring a second surgical intervention as a result of positive margins were assessed.Results
Patient and tumor characteristics and systemic treatment regimens were comparable between both groups. The median weight of the resected specimen (53 vs. 48 g), the median smallest margin (3.5 vs. 3.0 mm), and the risk for additional surgery for incomplete resections (7 vs. 8 %) did not differ significantly between patients treated with the ROLL-99mTc technique and 125I seed localization.Conclusions
The ROLL-99mTc technique and 125I seed localization demonstrate comparable results when used to perform breast-conserving surgery after neoadjuvant systemic treatment. Because 125I seed localization does not require additional radiological localization shortly before surgery, it simplifies surgery scheduling. Therefore, we prefer 125I seed localization to perform breast-conserving surgery after neoadjuvant systemic treatment. 相似文献17.
Simone M. De LA Rie Eric F. Van furth Annemieke De Koning Greta Noordenbos Marianne C. H. Donker 《Eating disorders》2013,21(4):345-351
Having a relative with an eating disorder (ED) affects the life of family caregivers and may thus affect their quality of life. To study this aspect, 40 caregivers of ED patients filled out a health-related quality of life questionnaire (Short Form-36) and a questionnaire on the impact of the ED on various areas of life domains, and on the relationship with the ED patient and the need for professional support. Quality of life of caregivers was worse than in a normal reference group. Specifically, mental health, vitality and emotional role functioning were reported to be most impaired. ED appeared to affect families’ lives substantially. In response to the ED, caregivers felt anxious, powerless, sad, or desperate. The relationship of the caregiver with the ED patient had also changed. Caregivers were more worried, lost their trust, and reported more conflicts. Seventy five percent welcomed professional support. Caregivers need practical advice, information on ED, and emotional support. Quality of life of caregivers should be addressed in the treatment of ED. 相似文献
18.
Proliferation of myeloid progenitor cells in human long-term bone marrow cultures is stimulated by interleukin-1 beta 总被引:3,自引:0,他引:3
Fibbe WE; Goselink HM; Van Eeden G; Van Damme J; Billiau A; Voogt PJ; Willemze R; Falkenburg JH 《Blood》1988,72(4):1242-1247
To study the effect of interleukin-1 (IL-1) beta on the proliferation of hematopoietic progenitor cells (HPC) in long-term bone marrow cultures (LTBMC), stromal cell layers were established from normal human bone marrow. Autologous cryopreserved mononuclear phagocyte- and T-lymphocyte-depleted bone marrow cells were reinoculated on the stromal layers in fresh culture medium, with or without the addition of human IL-1 beta (30 U/mL). Once a week, half of the culture supernatant was replaced with fresh culture medium with or without IL-1, and all nonadherent cells were returned to the flasks. At weekly intervals during a period of 5 weeks, one culture was sacrificed to determine the total number of cells and hematopoietic progenitor cells, present in the adherent and the nonadherent cell fractions. In IL-1-stimulated cultures, the number of cells recovered during a period of 5 weeks exceeded the number of cells in unstimulated control cultures by 1.5 times. This difference was attributed to a twofold increase in the number of adherent cells. The number of HPC recovered from IL-1- stimulated cultures was not different from that recovered from controls. The levels of colony-stimulating activity (CSA) in supernatants from IL-1-stimulated cultures were significantly higher than those in supernatants from control cultures. These results indicate that IL-1 enhances the recovery of cells in LTBMC by stimulating the proliferation of HPC with the concurrent release of CSA from stromal cells, without diminishing the number of HPC. 相似文献
19.
Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes 总被引:4,自引:1,他引:4
Aman MJ; Tretter T; Eisenbeis I; Bug G; Decker T; Aulitzky WE; Tilg H; Huber C; Peschel C 《Blood》1996,87(11):4731-4736
In the present study, we investigated the effect of interferon-alpha (IFN-alpha) on the expression of interleukin-10 (IL-10) mRNA and protein synthesis in human monocytes and CD4+ T cells. In mononuclear cells, IFN-alpha induced expression of IL-10 mRNA and further enhanced lipopolysaccharide (LPS)-stimulated IL-10 expression. In purified monocytes, a strong expression of IL-10 mRNA induced by LPS was not further enhanced by IFN-alpha. In highly purified CD4+ T cells, IFN- alpha upregulated IL-10 mRNA upon activation with phytohemagglutinin and phorbol myristate acetate. In purified monocytes, an effect of IFN- alpha on IL-10 protein synthesis was dependent on costimulation with LPS. Maximal stimulation of IL-10 protein by IFN-alpha was seen after prolonged incubation periods of 48 to 96 hours, whereas IFN-gamma reduced IL-10 production in the early incubation period. Similar effects of IFN-alpha were observed in CD4+ T cells activated with CD3 and CD28 monoclonal antibodies. Addition of IFN-alpha caused an increase of IL-10 in culture supernatants of activated T-helper cells of more than 100% after 96 hours of incubation. In contrast, other cytokines, including IFN-gamma and IL-4, had no influence on IL-10 secretion stimulated by CD3 and CD28 in CD4+ T cells. In serum samples of IFN-alpha-treated individuals, we failed to detect an influence of cytokine treatment on IL-10 serum levels, confirming the requirement of additional activating signals for IFN-alpha-mediated effects on IL-10 synthesis. In conclusion, IFN-alpha enhances the late induction of IL- 10, which physiologically occurs upon stimulation of monocytes and T cells. Biologically, this effect might enhance the negative-feedback mechanism ascribed to IL-10, which limits inflammatory reactions. 相似文献
20.
Federico Pappalardo Evgenij Potapov Antonio Loforte Michiel Morshuis David Schibilsky Daniel Zimpfer Julia Riebandt Christian Etz Matteo Attisani Mauro Rinaldi Assad Haneya Faiz Ramjankhan Dirk Donker Ulrich P Jorde Daniel Lewin Radi Wieloch Rafael Ayala Jochen Cremer Letizia Bertoldi Michael Borger Artur Lichtenberg Jan Gummert Diyar Saeed the Durable MCS after ECLS study group 《Interactive Cardiovascular and Thoracic Surgery》2022,34(4):676
Open in a separate window OBJECTIVESImplanting a durable left ventricular assist device (LVAD) in a patient on extracorporeal life support (ECLS) is challenging. The goal of this study was to compare the results of patients from a European registry who had a durable LVAD implanted with or without transition from ECLS to cardiopulmonary bypass (CPB).METHODSA total of 531 patients on ECLS support who had an LVAD implant between January 2010 and August 2018 were analysed; after 1:1 propensity score matching, we identified and compared 175 patients in each group.RESULTSThe duration of preoperative ECLS was 7 [standard deviation (SD) 6] vs 7 (SD 6) days in patients with or without CPB (P = 0.984). The surgical time was longer in the CPB group [285 (SD 72) vs 209 [SD 75] min; P ≤ 0.001). The postoperative chest tube output was comparable [1513 (SD 1311) vs 1390 (SD 1121) ml; P = 0.3]. However, re-exploration for bleeding was necessary in 41% vs 29% of patients with or without CPB (P = 0.01) and a significantly higher number of packed red blood cells and fresh frozen plasma [8 (SD 8) vs 6 (SD 4) units; P = 0.001 and 6 (SD 7) vs 5 (SD 5) units; P = 0.03] were administered to patients operated on with CPB. A postoperative mechanical right ventricular support device was necessary in 50% vs 41% of patients (P = 0.08). The stroke rate was not significantly different (P 0.99). No difference in survival was observed.CONCLUSIONSOmitting CPB for an LVAD implant in patients on ECLS is safe and results in shorter operating time, less re-exploration for bleeding and fewer blood products. However, no survival benefit is observed. 相似文献